Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma

Authors

  • Fanny Barel
  • Briac Guibourg
  • Laetitia Lambros
  • Glen Le Flahec
  • Pascale Marcorelles
  • Arnaud Uguen

DOI:

https://doi.org/10.2340/00015555-2738

Keywords:

melanoma, BRAF, NRAS, immunohistochemistry, Idylla, next-generation sequencing

Abstract

BRAF and NRAS genetic analyses are time-consuming and can delay treatment choices in patients with metastatic melanomas presenting with acute deterioration. We compared the rapid, real-time, fully automated molecular diagnosis platform Idylla? with next-generation sequencing (NGS) and immunohistochemistry for detection of BRAF and NRAS mutations in 36 patients with metastatic melanomas. The Idylla? NRAS-BRAF-EGFRS492R mutation assay (110 min per sample) detected BRAF and NRAS mutations in 15 and 17 samples, respectively. One NRAS mutation was different between NGS and Idylla? (NRASG13C vs. NRASG12A/D). Four samples were BRAF and NRAS wild-type. The global concordance between NGS and Idylla? assays was 97.2% (35/36 cases). Immunohistochemistry was positive only in 9/9 BRAFV600E- and 6/6 NRASQ61R-mutated samples with VE1 and SP174 antibodies, respectively. The Idylla? platform is a valuable rapid molecular diagnosis tool to reduce the delay in BRAF and NRAS analyses-related treatment choices for patients with metastatic melanoma presenting with acute deterioration.

Downloads

Download data is not yet available.

Downloads

Published

2017-09-14

How to Cite

Barel, F., Guibourg, B., Lambros, L., Le Flahec, G., Marcorelles, P., & Uguen, A. (2017). Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. Acta Dermato-Venereologica, 98(1), 44–49. https://doi.org/10.2340/00015555-2738

Issue

Vol. 98 No. 1 (2018): January

Section

Articles

License

Copyright (c) 2017 Fanny Barel, Briac Guibourg, Laetitia Lambros, Glen Le Flahec, Pascale Marcorelles, Arnaud Uguen

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC